RVO
HomeMarketplace

ProductUpdated on 1 September 2025

ORCA-010: Enhanced Oncolytic Immunotherapy Platform with 100% Immune Activation Success

Wenliang Dong

CEO at ORCA Therapeutics BV

Amsterdam, Netherlands

About

ORCA-010 is a breakthrough enhanced oncolytic immunotherapy platform achieving unprecedented 100% immune activation in cancer patients. Our technology consistently converts "cold" tumors to "hot" with >70x enhanced potency compared to existing oncolytic platforms.

Proven clinical results in prostate cancer include durable PSA decrease in 50% of patients and cancer-free biopsies in 33% at one-year follow-up, with excellent safety profile (Grade I-II AEs only, no MTD reached).

Our diversified pipeline targets high-value opportunities:

  • Metastatic prostate cancer (pivotal trial planned)

  • Recurrent glioblastoma (academic collaboration initiated)

  • Pediatric DIPG (orphan designation potential)

  • Pancreatic adenocarcinoma (high unmet need)

ORCA-010's platform approach enables expansion across multiple orphan oncology indications where immune activation could transform patient outcomes. The technology's ability to induce systemic anti-tumor responses creates opportunities for both monotherapy and combination strategies.

We seek strategic partnerships for co-development, licensing, or acquisition discussions across our indication portfolio, particularly in prostate cancer and rare oncology diseases with significant unmet medical need.

Best regards,

Wen

Wenliang Dong, PhD, MBA

Contact: wen.dong@orca-therapeutics.com

Similar opportunities

  • Project cooperation

    Neo-adjuvant oncolytic immune activator

    Wenliang Dong

    CEO at ORCA Therapeutics BV

    Amsterdam, Netherlands

  • Service

    Viral Vector Development & Manufacturing

    • Development
    • Manufacturing
    • Innovative therapies - Gene therapy
    • Innovative therapies - Oncolytic viruses

    Sophia Kolbe

    Business Developer at NecstGen

    Leiden, Netherlands

  • Service

    Oncolines cancer cell panel profiling

    • Consulting
    • Development
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Pre-clinical research and development

    Guido Zaman

    Managing Director at Oncolines B.V.

    Oss, Netherlands